EU/3/22/2712: Orphan designation for the diagnosis of AL amyloidosis

Iodine (124I) evuzamitide

Table of contents

Overview

This medicine was designated as an orphan medicine for the diagnosis of AL amyloidosis in the European Union on 11 November 2022.

This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a marketing authorisation.

Orphan designation does not mean the medicine is available or authorised for use. All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.

During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. For information on ongoing clinical trials in the EU, see:

Key facts

Active substance
Iodine (124I) evuzamitide
Intended use
Diagnosis of AL amyloidosis
Orphan designation status
Positive
EU designation number
EU/3/22/2712
Date of designation
11/11/2022
Sponsor

Regresponse Limited
Lee View House
12/13 South Terrace
Cork T12 T0CT
Co. Cork
Ireland
E-mail: info@attralus.com

 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating